The study’s preliminary results indicated that 49% ORR was achieved in patients with high MET amplification (defined as ≥10 gene copies in the FISH method) and/or high overexpression (defined as overexpression of MET on 90% of cancer cells in the IHC method). This evidence concerns the gene MET and cancer.